Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Frequently asked questions
What sector does Alkermes plc (ALKS) operate in?
Alkermes plc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Alkermes plc (ALKS) current stock price?
As of the latest data, Alkermes plc stock price is $49.45, with a previous close of $50.28. Alkermes plc lost -$0.83 in the last trading session, representing a -1.65% loss.
What is Alkermes plc (ALKS) current market capitalization?
Alkermes plc market cap is approximately 8.30 billion.
What is Alkermes plc (ALKS) Earnings Per Share (EPS)?
The trailing EPS is $0.40, and the forward EPS is $1.83.
What is Alkermes plc (ALKS) Price-to-Earnings (P/E) ratio?
Alkermes plc current P/E ratio is 123.63, with a forward P/E of 27.05.
What is Alkermes plc (ALKS) EBITDA?
Alkermes plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 54.32 million.
Does Alkermes plc (ALKS) pay dividends?
No. Alkermes plc does not pay a dividend.
How did Alkermes plc (ALKS) perform in its most recent earnings report?
In the last report (June 30, 2026), Alkermes plc posted an EPS surprise of 1,400% and a revenue surprise of 8.45%.
What is Alkermes plc (ALKS) beta (volatility) score?
Alkermes plc has a beta of 0.294, indicating lower volatility than the overall market.
